DKSH Acquires Rocephin Rights From Roche in More Than 80 Markets
- DKSH on October 28, 2026, announced the acquisition of rights to Roche's Rocephin antibiotic across more than 80 markets.
- Rocephin generated approximately CHF 61 million in net sales in 2025.
- The acquisition expands the higher-value Healthcare Own Brands portfolio, following the Meliane acquisition from Bayer announced in July 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2423180_en) on October 28, 2026, and is solely responsible for the information contained therein.